News Agency
Men's Weekly

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GE

  • Written by PR Newswire

HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus oxaliplatin (XELOX) compared...

Read more: Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis...

Gender-Inclusive Lash Treatments: Breaking Beauty Norms

Beauty is no longer defined by traditional gender standards, and the lash industry is evolving to reflect that.  In 2026, more clients of all genders are seeking lash lifts, tints, and extensions that enhance their natural features while respecting individual style... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion